Deal Ends Today·Save 35% annual plan
GLP-1 receptor agonistReviewed for 2026 plan year

Does Regence Cover Ozempic?

The verdict

Conditional on most plans

Regence covers Ozempic for type 2 diabetes with prior authorization on its commercial, ACA, and Medicare Advantage plans in Oregon, Washington, Idaho, and Utah. It is not covered for off-label weight-loss use under any Regence line of business. Formulary tier and copay details are not publicly confirmed at the drug level — verify on Regence's member drug lookup.

MedicareConditional
CommercialConditional
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Regence using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
Regence drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice

Key facts

  • Ozempic is FDA-approved for type 2 diabetes glycemic control and cardiovascular risk reduction in T2D adults with known heart disease — it is not FDA-approved for weight loss.

    FDA drug labeling, Ozempic (semaglutide injection)

  • The IRA Maximum Fair Price for semaglutide (Ozempic/Rybelsus/Wegovy combined) under Medicare is $274 per 30-day supply, effective January 1, 2027 — a 71% discount off the CY2024 list price.

    CMS, IRA Drug Price Negotiation Program, 2024

  • All 50 state Medicaid programs cover GLP-1 receptor agonists including Ozempic for type 2 diabetes; off-label weight-loss use is not covered under any state Medicaid program.

    KFF, Medicaid Coverage of and Spending on GLP-1s, 2026

Plan types

Medicare vs. commercial coverage

Whether Regence covers Ozempic depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Conditional

Medicare Advantage (Regence Medicare Advantage plans): Ozempic is covered for type 2 diabetes with prior authorization. PA requires a documented T2D diagnosis and metformin step-therapy (or documented intolerance/contraindication). The 2026 Part D $2,100 out-of-pocket cap limits annual beneficiary exposure. The IRA Maximum Fair Price for semaglutide is $274 per 30-day supply, effective January 1, 2027 — a material reduction for Medicare enrollees. Ozempic is not covered for weight loss on any Regence Medicare plan; off-label weight-loss use is statutorily excluded from Medicare Part D. Medicare enrollees cannot use the NovoCare savings card (federal anti-kickback rules).

Commercial / Employer

Group & marketplace plans

Conditional

Commercial/Employer: Regence covers Ozempic for type 2 diabetes with prior authorization and standard metformin step-therapy. Formulary tier is not publicly published at the drug level for Regence's many state-specific commercial plans — verify on Regence's drug lookup tool. Not covered for off-label weight loss under any employer or commercial plan. Commercially insured T2D patients may be eligible for the NovoCare Ozempic Savings Card ($25 per fill, max $150/28-day supply); not available to Medicare or Medicaid enrollees. ACA/Individual: covered for T2D with PA; not covered for weight loss. Medicaid: Regence is not the primary Medicaid MCO in Oregon, Washington, Idaho, or Utah; state Medicaid programs in these states cover Ozempic for T2D with PA and nominal cost-share ($0–$4 typical) through their own managed-care or fee-for-service programs — verify on your state Medicaid agency's drug list.

Prior authorization

The 2 boxes you must tick to get approved

Commercial plans that will consider Ozempic require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 2

Meet all 2 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

What you'll pay

Your cost, three ways

What Ozempic actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

~$1,028/month (Novo Nordisk published pricing). NovoCare self-pay: ~$199/month intro (first two fills through December 31, 2026), then ~$349/month (0.25/0.5/1 mg) or ~$499/month (2 mg).

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

Commercial/Employer: tier-based cost-share; specific tier and copay not publicly published — verify on Regence's drug lookup tool. Medicare Advantage: cost-share per plan design; $2,100 OOP cap 2026; IRA Maximum Fair Price $274/30-day effective January 1, 2027. State Medicaid (via state programs): $0–$4 nominal typical.

Typical monthly copay once prior authorization is approved.

Lowest cost

Bridge program

NovoCare Ozempic Savings Card: commercially insured T2D patients pay as little as $25 per fill (max $150 per 28-day supply). Not available to Medicare Advantage, Medicaid, VA, DoD, or TRICARE beneficiaries. Verify eligibility at NovoCare.com.

Reduced copay through the assistance program, where eligible.

All figures are estimates — tier placement and exact cost-share vary by specific Regence plan and are not publicly confirmed at the drug level. Verify on Regence's drug lookup or by calling Regence member services.

Do it yourself

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Use Regence's online drug lookup tool to confirm coverage and tier

    Visit regence.com and use the Find a Drug or formulary lookup tool with your specific plan ID to confirm Ozempic's formulary status, tier placement, and any prior-authorization or step-therapy requirements for your OR, WA, ID, or UT plan. Tier and copay vary by specific plan and are not published at the drug level in public documents.

  2. 2

    Have your prescriber submit the prior authorization for type 2 diabetes

    The PA submission requires a documented T2D diagnosis (ICD-10 E11.x) and evidence of metformin use — or a documented medical reason metformin is contraindicated or not tolerated. The clinical indication must be type 2 diabetes; a weight-management indication will not support PA approval under any Regence plan.

  3. 3

    Check NovoCare savings card eligibility if you have commercial coverage

    If you have a Regence commercial or employer-sponsored plan and a confirmed T2D diagnosis, visit NovoCare.com to enroll in the Ozempic Savings Card, which may reduce your out-of-pocket cost to as little as $25 per fill (max $150/28-day supply). This card is not available to Regence Medicare Advantage or Medicaid enrollees.

If it's denied

Options if Regence won't cover Ozempic

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

Rybelsus (oral semaglutide)

Oral semaglutide tablet approved for type 2 diabetes. Also covered for T2D with PA on most plans; also subject to the IRA Maximum Fair Price of $274/30-day for Medicare patients effective January 1, 2027. Verify tier on Regence's drug lookup.

Jardiance (empagliflozin)

SGLT-2 inhibitor commonly used as step therapy before or alongside Ozempic PA. Often available at a lower cost-share tier. Oregon, Washington, Idaho, and Utah Medicaid programs cover SGLT-2 inhibitors for T2D.

Wegovy (semaglutide 2.4 mg)

On-label for weight management. Regence's coverage for Wegovy for weight loss is not publicly confirmed in detail — employer-plan dependent. For the T2D indication, Ozempic is the on-label option; these are different drugs for coverage purposes.

Compounded semaglutide (weight-loss seekers only)

For patients seeking semaglutide for weight management who are denied under Regence, compounded semaglutide from $49/mo is available at getcurex.com/cl/glp without insurance. See the offer section below for full disclaimers.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

No. Regence does not cover Ozempic for weight loss under any line of business. Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction in T2D patients with known heart disease — it is not FDA-approved for weight management, and off-label weight-loss use is not a covered indication. If you are seeking semaglutide for weight management, Wegovy is the on-label option, and its coverage under Regence commercial plans depends on your specific employer benefit design.

Yes. Regence covers Ozempic for type 2 diabetes with prior authorization on its commercial, ACA, and Medicare Advantage plans in Oregon, Washington, Idaho, and Utah. PA requires a documented T2D diagnosis and evidence of metformin step-therapy. Formulary tier and exact copay are not publicly confirmed at the drug level for Regence's many regional plans — verify on Regence's drug lookup tool or by calling member services for your specific plan.

No. Regence is not the primary Medicaid managed-care organization in Oregon, Washington, Idaho, or Utah. State Medicaid coverage in these states (including Oregon Health Plan, Apple Health WA, and Idaho Medicaid) follows state PDL rules and is administered through separate managed-care contractors. All four state Medicaid programs cover Ozempic for type 2 diabetes with PA and nominal cost-share. If you have Medicaid, verify your coverage through your state Medicaid agency or managed-care plan, not through Regence.

Yes, if you have a Regence commercial or employer-sponsored plan and a confirmed T2D diagnosis. The NovoCare Ozempic Savings Card may reduce your cost to as little as $25 per fill (max $150/28-day supply). The card is not available to Regence Medicare Advantage or Medicaid enrollees — federal anti-kickback rules exclude government program beneficiaries. Verify current eligibility and program terms at NovoCare.com before assuming the card applies.

Regence requires a documented type 2 diabetes diagnosis and evidence of metformin step-therapy (or a documented reason metformin is contraindicated or not tolerated). Regence's specific PA criteria are not confirmed in a primary publicly available document at the drug level — the T2D-covered-with-PA pattern reflects the near-universal industry norm. Verify the exact criteria on Regence's prior-authorization page or by calling Regence member services before your prescriber submits the PA.

The Curex GLP-1 program

Insurance won't cover Ozempic for weight loss — here's a path that doesn't need it

Regence does not cover Ozempic for weight loss. For Pacific Northwest and Mountain West patients seeking semaglutide for weight management, Curex offers compounded semaglutide from $49/mo at getcurex.com/cl/glp — no Regence prior authorization required, no insurance needed. Compounded tirzepatide is also available from $149/mo. Compounded semaglutide is not the same medication as Ozempic or Wegovy. Prescription required, subject to provider review.

Compounded semaglutide
from$49/mo
Weekly injection or oral tablet
Compounded tirzepatide
from$149/mo
Injection or oral tablet
  • Medication + free shipping
  • 24/7 provider access
  • Medical intake & prescription review
From $49/moNo insurance requiredNo prior auth
Build your personalized planPrescription required, subject to provider review.

Compounded semaglutide and tirzepatide are not the same medications as Ozempic and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Regence before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Ozempic and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

Weight care with Curex

Insurance won't cover Ozempic for weight loss — here's a path that doesn't need it

Build your personalized plan

Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.